At week 48 in the per-protocol population , 112 ( 84 % ) of 133 patients had virological response in the dual-treatment group versus 105 ( 78 % ) of 135 in the triple-treatment group ( difference 6 % [ 95 % CI -5 to 16 % ) , showing non-inferiority at the prespecified level .